BACKGROUND: Vitamin D deficiency is the most common nutritional deficiency worldwide in all ages. Prolonged and severe vitamin D deficiency can result in secondary hyperparathyroidism and osteomalacia. Vitamin D deficiency can be caused by various factors included here institutionalisation, malabsorption, inadequate exposure to sunlight etc. Osteomalacia is a disorder of decreased mineralisation of newly formed osteoid at sited of bone turnover, which can be manifested with symptoms such as diffuse body aches and pain. Muscles weakness from vitamin D deficiency causes difficulty in walking, developing proximal myopathy. Nearly 30-50% of all age groups are Vitamin D deficient worldwide. CASE PRESENTATION: We report a case of 51-years-old woman, with a religious garment, with slowly progressing weakness of the proximal limb muscles, extreme fatigue, chest and lower spine pain, paresthesia, depression, difficulties in walking and waddling gait. On whole-body bone scintigraphy diffuse metabolic changes were present, and in DXA osteoporosis was shown due to severe vitamin D deficiency and secondary hyperparathyroidism. Treatment with high doses of vitamin D and calcium replacement improved clinical manifestation of osteomalacia for few months. Absent of waddling gait with no pain was evident due to the better muscle and bone performance after the treatment. CONCLUSION: Suspicious cases for osteomalacia in population wearing a religious garment and those that are not adequately exposed to the sunlight, laboratory evaluation should include measurement of 25 (OH) vitamin D, PTH, calcium, alkaline phosphatase and performing of DXA in order such cases do not get undiagnosed.
Several studies have demonstrated the decreased insulin resistance (IR) in persons with type 2 diabetes mellitus (T2DM) treated with glimepiride. Those suggest this might be associated with observed higher concentrations of adiponectin. We assessed if there is a difference in IR and metabolic syndrome components between glimepiride and glibenclamide treatment as well as adiponectin concentration in T2DM. Our research observed 20 T2DM patients treated with glibenclamid and 20 switched to glimepiride (n = 20) treatment for 24 weeks. Anthropometric measurements and laboratory analysis were performed at the beginning and at the end of treatment while IR was accessed by homeostasis model assessment of insulin resistance (HOMA-IR). The glimepiride group revealed better glycaemic control compared to glibenclamide group. Moreover, the adiponectin concentration increased (23.9 ± 17.3 to 29.1 ± 12.2 ng/mL, p = 0.087) whereas it decreased in the glibenclamide group (34.3 ± 22.6 to 20.3 ± 11.3 ng/mL, p = 0.011) following 24 weeks of treatment. The serum adiponectin and HOMA-IR were inversely correlated within the group of glibenclamide (r = -0.667, p = 0.009). The present study demonstrates that glimepiride might have beneficial effect on IR compared to glibenclamide, as suggested. However, this observation needs further study investigation among other formulations of SU.
BACKGROUND: Gestational diabetes mellitus (GDM) is a condition increasing yearly worldwide. AIM: We investigated the prevalence and the arrangement of common risk predictors for developing GDM among Kosova pregnant women after 24 gestational weeks. MATERIALS AND METHODS: A total of 202 hospitalized pregnant women participated in this prospective study. All participants underwent a detailed clinical examination for risk factors for GDM, followed by appropriate biochemical blood analysis and anthropometric measurements. The glucose tolerance test results were interpreted according to the criteria established by the World Health Organization (WHO) and American Diabetes Association. Participants in the first part of the study were divided into the four risk groups and in the second part GDM group (case group) or a normal glucose tolerance group (control group) to determine the risk factors for GDM and associated clinical and biochemical predictors. RESULTS: The prevalence of gestational diabetes was 5.9%.The average age was 30.0 ± 5.5. Main characteristics of high-risk group of women for GDM were: ages above 30-year-old (p = 0.001), positive glucose intolerance (p = 0.0001), personal history for GDM (p = 0.0001), familiar history for DM (p = 0.0001), obesity (p = 0.0001), previous childbirth with weight higher than 4000 g (p = 0.0001), vulvovaginal infection (p = 0.0001), and polyhydramnios (p = 0.0001). Almost the same characteristics were found also for the GDM group: Like personal history for GDM (p = 0.0018), and family history for DM (p = 0.0018). Moreover, the group with GDM was characterized with significantly higher laboratory parameters such as fasting glycemia (p = 0.0000), triglycerides, and cholesterol concentrations (p = 0.0001). Anthropometric measurements such as weight (p = 0.002), body mass index (p = 0.0015), and systolic (p = 0.0163) and diastolic (p = 0.042) blood pressure were also significantly higher than the control group. CONCLUSIONS: Older age, family history of diabetes and personal history for GDM, polyhydramnios, stillbirth >4000 g, were significant risk factors for GDM. Screening for risk factors can easily bring at GDM early diagnosis and prevention. Public awareness-raising on the risk factors for GDM and the need for early screening should be strongly pursued, particularly for the women at risk for GDM, especially in developing countries. At every level of health service, GDM screening to pregnant women should be incorporated as a routine antenatal visit.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.